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(57) ABSTRACT 
Embodiments of the presently-disclosed subject matter pro 
vide an isolated polypeptide comprising the sequence of SEQ 
ID NO: 1, fragments thereof, and/ or epitopes thereof. 
Embodiments of the presently-disclosed subject matter also 
provide methods for diagnosing a Strongylus vulgaris infec 
tion in a subject that comprises providing a biological sample 
from the subject and contacting the sample with the present 
isolated polypeptide, fragment thereof, and/or epitope 
thereof. In some embodiments the Strongylus vulgaris infec 
tion can be detected during a prepatent period. In further 
embodiments the subject is a horse. 
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DIAGNOSIS OF ST RONGYL US VULGARIS 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Patent Application No. 61/719,762, ?led Oct. 29, 2012, the 
entire disclosure of which is incorporated herein by this ref 
erence. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to diagnosis 
of pathogenic parasites. In particular, the presently-disclosed 
subject matter relates to diagnosis of Slrongylus vulgaris in a 
subject, including a horse. 
INTRODUCTION 
The lifecycle of S. vulgaris is characterized by a long 
prepatent period when the migrating larvae are virtually 
undetectable, which poses an unsolved challenge for diagno 
sis. Strongyle parasites are ubiquitous in grazing horses with 
more than 50 different species described (Lichtenfels et al., 
2008). The most pathogenic of the gastrointestinal parasites 
infecting horses, Slrongylus vulgaris, belongs to the large 
strongyles that are known for their extensive tissue migration 
and a long prepatent period of 6-7 months (Round, 1969). 
During this time, S. vulgaris larvae migrate in the arteries that 
supply large portions of the intestinal tract, with the cranial 
mesenteric artery and major branches being the predilection 
site (Enigk, 1970; Duncan and Pirie, 1972). Here, the larvae 
cause verminous endarteritis with aneurysm and thrombus 
formation, leucocytic in?ltration and ?brosis of the arterial 
wall (Drudge et al., 1966; Duncan and Pirie, 1975; Morgan et 
al., 1991). The presence of the larvae can lead to a non 
strangulating infarction of portions of the intestinal tract, 
often known as verminous thromboembolic infarction (Cur 
tis, 1964; Enigk, 1970). 
Historically, S. vulgaris was prevalent (80-100%) (Bol 
linger, 1870; Slocombe and McCraw, 1973) and a parasite 
control strategy, the interval dose regimen, was used to con 
trol this parasite (Drudge and Lyons, 1966). This regimen was 
based on knowledge of the S. vulgaris life cycle as well as the 
mechanism of action of the available anthelmintic drugs. The 
interval dose regimen became widely implemented, and in 
the past couple of decades the prevalence of S. vulgaris based 
on coprology was greatly reduced in horses that were treated 
regularly (Hoglund et al., 1997; Pilo et al., 2011). 
With the emergence of anthelmintic resistance among the 
cyathostomins (small strongyles) and Parascaris equorum, 
emphasis has been oriented towards an epidemiological 
approach to helminth control (Herd et al., 1985), with tar 
geted selective therapy advocated to ensure anthelmintic e?i 
cacy in the future (Kaplan, 2002, 2004). In the European 
Union, prescription-only restrictions on anthelmintic drugs 
have been or are being implemented by legislation of member 
countries. This ensures that only a veterinarian can prescribe 
the anthelmintic drug after a diagnosis of parasite infection 
has been reached. Experiences from Denmark with prescrip 
tion-only limitations and selective anthelmintic therapy show 
that a reduction in treatment intensity follows (Nielsen et al., 
2006). Recently, it was shown that reduced treatment inten 
sity in Denmark allow for higher prevalence of S. vulgaris 
(Nielsen et al., 2012). Thus, there exists a need for improved 
diagnostic assays in order to better control this parasite while 













The lifecycle of S. vulgaris is characterized by a long 
prepatent period when the migrating larvae are nearly or 
completely undetectable, which poses an unsolved challenge 
for diagnosis. Currently, diagnosis of S. vulgaris infection is 
based on the presence of eggs shed by adult females in faeces 
of infected horses; this is accomplished currently either by 
larval culture and subsequent microscopic examination (Rus 
sell, 1948; Bevilaqua et al., 1993) or by a semi-quantitative 
PCR (Nielsen et al., 2008). So far, no test has been developed 
to accurately diagnose the presence of migrating larvae in the 
cranial mesenteric artery. Furthermore, an apparent increase 
in prevalence of S. vulgaris has been observed in regions 
where reduced anthelmintic treatment intensity has been 
implemented. 
These issues highlight the need for accurate and reliable 
tools for prepatent diagnosis of S. vulgaris infection. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes images of silver stained gel showing silver 
staining for Slrongylus vulgaris (Lane A) larval and (Lane B) 
adult excretory/ secretory (ES) fractions where low range 
molecular markers are shown to the left, and where Western 
blots are shown for (Lane C) reactivity of pre-immunisation 
rat serum against larval ES, (Lane D) reactivity of anti-adult 
S. vulgaris ES probed against larval ES, (Lane E) anti-adult S. 
vulgaris ES probed against adult ES, and (Lane F) reactivity 
of anti-adult S. vulgaris ES against larval ES where low range 
molecular markers are shown to the right. 
FIG. 2 includes A) ClustalOmega pairwise alignment of 
Slrongylus vulgaris SXP (SvSXP) (SEQ ID NO: 1) (acces 
sion number: KC155360) With Cylicostephanus goldi SXP 
partial homologue (SEQ ID NO: 2), Necalor americanus 
surface-associated antigen (Na-SAA) (ACE79378.1) (SEQ 
ID NO: 3), Ancylosloma caninum immunodominant hypo 
dermal antigen (Ac16) (ABD98404.1) (SEQ ID NO: 4), 
Ascaris suum 14 kDa antigen (As14) (BAB67769.1) (SEQ ID 
NO: 5),Ascaris lumbricoides antigen 1 (Ag1) (ADB45853.1) 
(SEQ ID NO: 6), and Parascaris equorum partial homologue 
(SEQ ID NO: 7), where the signal peptide for each sequence 
is underlined and the domain of unknown function (DUF148) 
is boxed, asterisks (*) denote identical amino acids, double 
dots (:) denote conserved amino acid changes, a single dot (.) 
denotes semi-conserved amino acid changes, hyphen (-) indi 
cates that a space was inserted in the sequence to improve 
alignment, and the percent similarity to SvaP is listed for 
each homologous protein, and includes B) a phylogenetic tree 
of the above mentioned sequences. 
FIG. 3 includes a Western blot analysis of pre-immunisa 
tion guinea pig serum (Lanes A and C) and hyperimmune 
anti-rSvSXP guinea pig serum (Lanes B and D) against 
rSvSXP (Lanes A and B) and Slrongylus vulgaris larval 
excretory/ secretory antigens (Lanes C and D). The molecular 
weight markers are shown to the left of each type of antigen. 
FIG. 4 includes Western blot showing 233 ng recombinant 
SvSXP (Lanes 1-8, box) probed with serum from Slrongylus 
vulgaris negative horse and (Lanes 9-15) probed with serum 
from S. vulgaris positive horses. The molecular weight is 
indicated on the left size. 
FIG. 5 includes a boxplot showing optic density readings 
of the enzyme-linked immuno sorbent assay with antigen spe 
ci?c IgG subclasses grouped by Slrongylus vulgaris infection 
status. —: no S. vulgaris larvae; +: S. vulgaris larvae present in 
the cranial mesenteric artery or branches. The middle black 
line of the box is the median and the range of the box is the 
inter quartile range (IQR) giving the ?rst and third IQR. The 
lower and upper lines are up to 1.5 IQR away from the ?rst 
US 8,951,741 B1 
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and third quartile. Each square represents the mean OD450nm 
reading from one serum sample for each IgG subclass. Aster 
isks denote signi?cant differences (p<0.05) between unin 
fected and infected horses within each IgG subclass. 
FIG. 6 includes graphs of the relationship between serum 
anti-rSvSXP IgG(T) antibody levels (expressed as percentage 
of a positive control) and counts of migrating Slrongylus 
vulgaris larvae categorised by their number of larvae showing 
a) all 102 horses in the data set and b) the 86 horses in the data 
set aged 7 months and older. Group 0: No larvae, migratory 
tracts nor evidence of previous infection (FIG. 6a: n:42; FIG. 
6b: n:28); group 1: Migratory tracts or evidence of previous 
infection (n:16); group 2: 1-5 larvae (n:16); group 3: 6-25 
larvae (n:17); and group 4: >25 larvae (FIG. 6a: n:11; FIG. 
6b: n:9). The middle black line of the boxes is the median and 
the range of the box is the inter quartile range (IQR) giving the 
?rst and third IQR. The lower and upper lines are up to 1.5 
IQR away from the ?rst and third quartile. Groups with dif 
ferent letters are signi?cantly different (P-value <0.05). 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTINGS 
SEQ ID NO: 1 is an amino acid sequence encoding an 
embodiment of an isolated Slrongylus vulgaris SXP (SvSXP) 
peptide. 
SEQ ID NO: 2 is an amino acid sequence encoding an 
embodiment of an isolated Cylicoslephanus goldi SXP partial 
homologue. 
SEQ ID NO: 3 is an amino acid sequence encoding an 
embodiment of an isolated Necalor americanus surface-as 
sociated antigen (N a-SAA). 
SEQ ID NO: 4 is an amino acid sequence encoding an 
embodiment of an isolated Ancylosloma caninum immun 
odominant hypodermal antigen (Ac 1 6). 
SEQ ID NO: 5 is an amino acid sequence encoding an 
embodiment of an isolated Ascaris suum 14 kDa antigen 
(Asl4). 
SEQ ID NO: 6 is an amino acid sequence encoding an 
embodiment of an isolated Ascaris lumbricoides antigen 1 
(Ag1). 
SEQ ID NO: 7 is an amino acid sequence encoding an 
embodiment of an isolated Parascaris equorum partial SEQ 
ID NO: 8 is an amino acid sequence encoding an embodiment 
of an isolated SvSXP epitope is selected from C-Ahx 
FANAGSMTDAAI-amide (svar-1). 
SEQ ID NO: 9 is an amino acid sequence encoding an 
embodiment of an isolated SvSXP epitope is selected from 
C-AFAAFEKEIQSAQAQ-amide (svar-2). 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of con?ict, the speci?cation of this docu 
ment, including de?nitions, will control. 
The presently-disclosed subject matter includes methods, 
puri?ed antibodies, isolated polypeptides, and kits useful for 












In some embodiments, a method of diagnosing a Slrongy 
lus vulgaris infection in a subject is provided. In speci?c 
embodiments the Strong/[us vulgaris infection is diagnosed 
during a prepatent period. Exemplary methods of diagnosing 
Slrongylus vulgaris include providing a biological sample 
from the subject; and contacting the sample with a polypep 
tide. In some embodiments, the polypeptide can be the 
polypeptide of SEQ ID NO: 1 and/or a fragment thereof. 
Exemplary fragments of the polypeptide of SEQ ID NO: 1 
can include at least 145, 144, 143, 142, 141, 140, 139, 138, 
137,136,135,134,133,132,131,130,129,128,127,126, 
125, 124, 123, 122, 121, 120, 119, 118, 117, 116, or 115 
amino acid residues. In some embodiments, the polypeptide 
includes an epitope of the polypeptide of SEQ ID NO: 1, 
wherein the epitope is selected from C-Ahx-FANAGSMT 
DAAI-amide (svar-1)(SEQ ID NO: 8) and/or 
C-AFAAFEKEIQSAQAQ-amide (svar-2)(SEQ ID NO: 9). 
The terms “diagnosing” and “diagnosis” as used herein 
refer to methods by which the skilled artisan can estimate and 
even determine whether or not a subject is suffering from a 
given disease or condition. The term diagnose or the like is 
inclusive of “prognosis” or “prognosticating,” which is an 
area of interest since it can be useful to know the relative risk 
associated with particular conditions in order to plan the most 
effective therapy. If an accurate prognosis can be made, 
appropriate therapy, and in some instances less severe therapy 
or more effective therapy, for the patient can be chosen. In 
some embodiments of the presently disclosed subject matter, 
a method includes identifying a subject as having a Slrongylus 
vulgaris infection, including one during a prepatent period. 
The term diagnosis can include determining a 10%, 20%, 
30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% likelihood 
that the subject is suffering from a given disease or condition 
(e.g., Strong/[us vulgaris infection). 
In some embodiments, the method also includes detecting 
antibodies in the sample that speci?cally bind the polypep 
tide. Any method known to one of ordinary skill in the art can 
be used for such detection. For example, in some embodi 
ments, the detection is conducted using an enzyme-linked 
immunosorbent assay (ELISA). In some embodiments, the 
subject is diagnosed as being infected by migrating S. vul 
garis larvae when antibodies that speci?cally bind the 
polypeptide are detected in the sample. 
The term “subject,” as used herein, is inclusive of animal 
subjects. Thus, veterinary uses are provided in accordance 
with the presently disclosed subject matter and the presently 
disclosed subject matter provides methods for preventing 
oxidative damage in animals. In speci?c embodiments the 
subject is a member of the Equidae taxonomic family. In some 
embodiments, the subject is a member of the Equus genus, 
including, for example, donkeys, mules, zebras, domesticated 
horses, przewalski, etc. In some embodiments, the subject can 
be a horse, including, for example, Equusferus, and including 
subspecies Equusferus caballus and Equusferusprzewalskii. 
Furthermore, the biological sample can be any sample of 
biological tissue, cells, or ?uids obtained from the subject. 
Exemplary samples include a blood sample from a subject. 
Another exemplary sample includes a serum sample from a 
subject. Further exemplary samples can include other bio 
logical ?uids, such as peritoneal ?uid or cerebrospinal ?uid. 
In some embodiments of the presently-disclosed subject 
matter, a method of diagnosing a Slrongylus vulgaris infec 
tion in a subject during a prepatent period is provided and 
involves providing a biological sample from the subject; and 
contacting the sample with a puri?ed antibody that speci? 
cally binds to an epitope of the polypeptide of SEQ ID NO: 1. 
In some embodiments, the epitope comprises the amino acid 
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residues of SEQ ID NO: 1 selected from C-Ahx 
FANAGSMTDAAI-amide (svar-1)(SEQ ID NO: 8) and/or 
C-AFAAFEKEIQSAQAQ-amide (svar-2)(SEQ ID NO: 9). 
In some embodiments, the method also involves detecting a 
polypeptide in the sample to which the antibody speci?cally 
binds. Any method known to one of ordinary skill in the art 
can be used for such detection. For example, in some embodi 
ments, the detection is conducted using an enzyme-linked 
immunosorbent assay (ELISA). In some embodiments, the 
subject is diagnosed as being infected by migrating S. vul 
garis larvae when the polypeptide to which the antibody 
speci?cally binds is detected in the sample. It is contemplated 
that in some embodiments of the method, the biological 
sample is a blood or a serum sample. 
The presently-disclosed subject matter further includes an 
isolated polypeptide molecule, comprising the sequence of 
SEQ ID NO: 1 or a fragment thereof. Such fragment can 
include, for example, at least 145, 144, 143, 142, 141, 140, 
139,138,137,136,135,134,133,132,131,130,129,128, 
127,126,125,124,123,122,121,120,119,118,117,116,or 
115 amino acid residues of SEQ ID NO: 1. The fragment of 
the isolated peptide can comprise amino acids that have been 
removed from the carboxy-terminus, the amino-terminus, or 
both terminuses of the isolated polypeptide of SEQ ID NO: 1. 
In some embodiments the isolated peptide further comprises 
on or more amino acid substitutions, and is therefore a variant 
of the isolated polypeptide of SEQ ID NO: 1. The presently 
disclosed subject matter further includes an isolated polypep 
tide molecule, comprising one or more epitopes of SEQ ID 
NO: 1 selected from C-Ahx-FANAGSMTDAAI-amide 
(svar-1)(SEQ ID NO: 8), and C-AFAAFEKEIQSAQAQ 
amide (svar-2)(SEQ ID NO: 9). Such isolated polypeptide 
molecules can be made using techniques known to one of 
ordinary skill in the art, e.g., various molecular biological 
techniques for producing recombinant polypeptide mol 
ecules. 
The terms “polypeptide”, “protein”, and “peptide”, which 
are used interchangeably herein, refer to a polymer of the 
protein amino acids, or amino acid analogs, regardless of its 
size or function. The term “polypeptide” as used herein refers 
to peptides, polypeptides, and proteins, unless otherwise 
noted. The terms “protein”, “polypeptide”, and “peptide” are 
used interchangeably herein when referring to a gene product. 
Thus, exemplary polypeptides include gene products, natu 
rally occurring proteins, homologs, orthologs, paralogs, frag 
ments and other equivalents, variants, and analogs of the 
foregoing. 
The term “isolated”, when used in the context of an isolated 
nucleotide or an isolated polypeptide, is a nucleotide or 
polypeptide that, by the hand of man, exists apart from its 
native environment and is therefore not a product of nature. 
An isolated nucleotide or polypeptide can exist in a puri?ed 
form or can exist in a non-native environment such as, for 
example, in a transgenic host cell. 
The presently-disclosed subject matter further includes a 
puri?ed antibody that speci?cally binds a polypeptide mol 
ecule as disclosed herein. In some embodiments, the puri?ed 
antibody speci?cally binds an epitope of the polypeptide of 
SEQ ID NO: 1. In speci?c embodiments the epitope of the 
polypeptide of SEQ ID NO: 1 comprises the amino acid 
residues of SEQ ID NO: 1 selected from C-Ahx 
FANAGSMTDAAI-amide (svar-1)(SEQ ID NO: 8) and/or 
C-AFAAFEKEIQSAQAQ-amide (svar-2)(SEQ ID NO: 9). 
In some embodiments, the antibody is a monoclonal anti 
body. 
The presently-disclosed subject matter further includes 












polypeptide of SEQ ID NO: 1 and/or a fragment thereof 
comprising at least 145, 144, 143, 142, 141, 140, 139, 138, 
137,136,135,134,133,132,131,130,129,128,127,126, 
125, 124, 123, 122, 121, 120, 119, 118, 117, 116, or 115 
amino acid residues; or a polypeptide comprising an epitope 
of the polypeptide of SEQ ID NO: 1, wherein the epitope is 
selected from C-Ahx-FANAGSMTDAAI-amide (svar-1) 
(SEQ ID NO: 8) and/ or C-AFAAFEKEIQSAQAQ-amide 
(svar-2)(SEQ ID NO: 9). The kit can further comprise a 
substrate con?gured to receive a biological sample from a 
subject. In some embodiments, the polypeptide can be immo 
bilized on a substrate. In some embodiments, the kit further 
includes reagents useful for detecting a binding between the 
polypeptide and an antibody in a biological sample. 
In some embodiments, a kit can include an antibody that 
speci?cally binds an epitope of the polypeptide of SEQ ID 
NO: 1 , wherein the epitope comprises the amino acid residues 
of SEQ ID NO: 1 selected from: C-Ahx-FANAGSMTDAAI 
amide (svar-1)(SEQ ID NO: 8) and/ or 
C-AFAAFEKEIQSAQAQ-amide (svar-2)(SEQ ID NO: 9). 
The kit can further comprise a substrate con?gured to receive 
a biological sample from a subject. In some embodiments, the 
antibody can be immobilized on a substrate. In some embodi 
ments, the kit further includes reagents useful for detecting a 
binding between the antibody and a polypeptide in a biologi 
cal sample. 
Unless de?ned otherwise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
“a”, “an”, and “the” refer to “one or more” when used in this 
application, including the claims. Thus, for example, refer 
ence to “a polypeptide” includes a plurality of such cells, and 
so forth. 
Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 120%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. 
As used herein, ranges can be expressed as from “about” 
one particular value, and/or to “about” another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as “about” that particular value in addition to the value itself. 
For example, if the value “10” is disclosed, then “about 10” is 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 and 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
The presently-disclosed subject matter is further illustrated 
by the following speci?c but non-limiting example. The fol 
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lowing example may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention. 
EXAMPLE 
This Example employed immunoscreening of a S. vulgaris 
larval cDNA library to identify genes that encode stage-spe 
ci?c antigens. This Example also used these in immunodiag 
nostic assays for a prepatent diagnosis of S. vulgaris. 
Materials and Methods 
Horses 
A total of 102 horses with necropsy-con?rmed status of S. 
vulgaris infection were enrolled in the validation study. All 
necropsies were performed at either University of Kentucky 
in Lexington, Ky. or East Tennessee Clinical Research 
(ETCR) in Rockwood, Tenn. 
All horses from University of Kentucky were naturally 
infected with mixed species of gastrointestinal helminth 
infections (n:31). They were enrolled from two main popu 
lations; a herd kept without anthelmintic intervention since 
1979, and a population of research horses maintained with 
four anthelmintic treatments a year. Naturally infected horses 
from Tennessee (n:23) participated in different anthelmintic 
drug trials at ETCR and all underwent necropsy. In total, 
samples from 54 naturally infected horses were collected. 
Experimental infections were carried out for two different 
research projects with horses maintained at ECTR (n:48). 
Horses in group P (n:20) were treated once daily for ?ve 
consecutive days with fenbendazole paste (10 mg/kg, Pana 
cur, Merck, Summit, N.J.), housed in stables and inoculated 
on a single occasion with 600 embryonated P. equorum eggs 
obtained locally from naturally infected horses. After six 
months the horses were euthanatised and necropsied. Horses 
in group S (n:28) were acquired with unknown anthelmintic 
treatment history, and were therefore treated with a larvicidal 
regimen of moxidectin (0.4 ug/kg, Quest gel, P?zer, Madison, 
N.J.) administered once, and fenbendazole paste (10 mg/kg, 
Panacur) once daily for ?ve consecutive days during the week 
prior to enrolment. They were subsequently infected with 
5,000 cyathostomin third stage larvae (L3) ?ve times weekly 
throughout the study. Five weeks into the study the horses 
started receiving 25 S. vulgaris L3 larvae once weekly until 
euthanasia and necropsy after 5.5 months. 
At necropsy, the posterior aorta and cranial mesenteric 
artery and branches were recovered and evaluated for the 
presence of migrating S. vulgaris larvae in all horses. 
The case-de?nition that served as the standard for classi 
?cation of S. vulgaris positive horses was: horses with migra 
tory tracts, one or more larvae, or evidence of previous infec 
tion. Migratory tracts were considered evidence of a current 
infection, and a circular area with raised surface, roughened 
or corrugated intima without evidence of active thrombosis 
was classi?ed as evidence of previous infection. Horses with 
no migratory tracts, no larvae, and no signs of previous infec 
tion were classi?ed as being S. vulgaris-negative. 
The gastrointestinal and migrating parasites were enumer 
ated as previously described. 
A peripheral blood sample was collected from each horse 
(n:102) in a serum or serum-separator tube. Sera were sepa 
rated by centrifugation, and duplicate aliquots were trans 
ferred to 2 mL cryovials and stored at —20° C. until analysis. 
The serum was stored for up to 5 years prior to analysis. 
The horses in this study had a mean age of 19.5 months 
(range 0.6 months-22 years) with a median of 12 months of 












which 12 were castrated. Data on age and gender was missing 
for two and one horse, respectively. The subset of horses 7 
months and older had a mean age of 22.51 months (range 7 
months-22 years) with a median of 18 months of age with 44 
female, 42 males of which 12 were castrated. Data from 
horses 3 months and younger were omitted; the next youngest 
foal was 7 months old. Breeds represented included: Tennes 
see Walking Horse, Paint, American Quarter Horse, Thor 
oughbred, Standardbred, Appaloosa, Shetland type ponies 
and mixed light breed. 
Parasite Material 
Migrating S. vulgaris larvae were collected by dissection 
of the abdominal aorta, celiac artery, cranial mesenteric artery 
and major branches recovered from horses at the University 
of Kentucky that were naturally infected with gastrointestinal 
parasites and where anthelmintic drugs have not been used 
since 1979. The larvae were carefully lifted from the throm 
bus material and washed four times in 20 mL PBS (137 mM 
NaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4) to remove 
debris. The larvae were either placed in 2 mL cryotubes and 
snap frozen in liquid N2 for RNA extraction or used for 
collection of ES antigens. 
Worms were collected from the caeca of horses using the 
necropsy technique previously described, adult S. vulgaris 
worms were identi?ed by morphological criteria and washed 
?ve times in 20 mL PBS to remove debris and used for 
collection of ES antigens. 
Excretory/ Secretory Antigens 
Living washed adult worms were incubated in 5 mL RPMI 
1640 (Life Technologies, Grand Island, N.Y.) with penicillin 
(100 IU/mL), streptomycin (100 IU/mL), amphotericin B 
(0.25 ug/mL) and a protease inhibitor cocktail (Protease 
inhibitor cocktail, P2714, Sigma-Aldrich, St. Louis, Mo.) in a 
5% CO2 incubator at 37° C. The medium was collected after 
12 and 24 h and fresh medium was added. The protein con 
centration was analysed using the Bradford Protein quantita 
tion assay (Pierce, Rockford, Ill.) as per the manufacturer’s 
protocol. The ES antigen-rich medium was then dialysed 
against PBS at 4° C. using a 3 mL 3.5 kDa molecular cut-off 
Slide-A-Lyzer® (Pierce, Rockford, Ill.) according to the 
manufacturer’ s protocol. Dialysed ES antigen was frozen and 
shipped to Cocalico Biologicals, Inc. (Reamstown, Pa.) for 
production of hyperimmune serum. One rat was immunised 
with 250 pg adult S. vulgaris ES antigen mixed with Titer 
max® as adjuvant and given as six inoculations over a 61 -day 
period. Due to background reactivity against E. coli proteins, 
the hyperimmune rat serum was pre-absorbed extensively 
against E. coli XL1-BLUE lysates. 
Larval ES antigens were obtained from S. vulgaris larvae 
using 2 mL of RPMI-1640 (Life Technologies, Grand Island, 
N.Y.) with penicillin (100 IU/mL), streptomycin (100 
IU/mL), amphotericin B (0.25 ug/mL) and a protease inhibi 
tor cocktail (Protease inhibitor cocktail, P2714, Sigma-Ald 
rich, St. Louis, Mo.) and incubating the larvae in a 5% CO2 
incubator at 37° C. The medium was collected after 14 days 
during which time the dead larvae were removed daily with a 
sterile needle. 
A total of 300 ng of S. vulgaris larval ES antigens was 
adjusted to 15 uL with water and mixed with 3 uL 5>< sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS 
PAGE) sample buffer containing protease inhibitor cocktail. 
The same amount of S. vulgaris adult ES was prepared simi 
larly. The ES mixtures were denatured at 95° C. for 5 min, 
placed on ice for 5 min and resolved in individual wells under 
reducing conditions in a 12% polyacrylamide gel, where after 
the gel was stained by silver staining 
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Construction and Immunoscreening of Larval S. vulgaris 
cDNA Library 
RNA was extracted from N2 frozen S. vulgaris larvae using 
the Trizol reagent (Life Technologies, Grand Island, N.Y.) 
and poly(A)+RNA (mRNA) was puri?ed from total RNA 
using the NucleoTrap® mRNA-kit (Clontech, Mountain 
View, Calif.) according to the manufacturer’s protocol. A 
total of 400 ng puri?ed mRNA was used as template to 
synthesise cDNA using the SMART cDNA library construc 
tion kit (Clontech, Mountain View, Calif.), cloned into bac 
teriophage TriplEx2 lambda vector digested with NdeI and 
packaged using the Giga Pack III gold packaging extract 
(Agilent Technologies, Stratagene products division, La 
Jolla, Calif.) as previously described for a larval cyathos 
tomin cDNA library. The titre of the cDNA library was evalu 
ated and the quality was assessed by analysing cDNA inserts 
in 30 randomly-picked plaques by PCR analysis. The PCR 
products were cleaned using the Wizard® SV Gel and PCR 
clean-up system (Promega, Madison, Wis.) and sequenced at 
the University of Kentucky (Lexington, Ky.). 
The S. vulgaris larval cDNA library was immunoscreened 
as described by the manufacturer (Clontech, Mountain View, 
Calif.). The primary immunoscreening was conducted on 
100,000 cDNA clones. Plaque lifts were made onto nitrocel 
lulose membranes (Fisher Scienti?c, Pittsburgh, Pa.) and the 
membranes were washed ?ve times for 5 min in 25 mL TBST 
(100 mM Tris, 0.15 M NaCl and 0.05% Tween-20) and kept 
in TBST overnight at 4° C. The membranes were blocked 
with TBST+1% gelatine for 1 h at room temperature (RT) and 
probed with preabsorbed hyperimmune rat serum at 1:100 in 
TBST after washing. As secondary antibodies, horseradish 
peroxidase (HRP)-conjugated goat anti-rat IgG (H+L) (Jack 
son ImmunoResearch, Inc. West Grove, Pa.) were used at 
1:10,000 in TBST after washing. The signal was developed 
using a chromogenic substrate (TMB stabilised substrate for 
HRP, Promega, Madison, Wis.) after washing. The mem 
branes were aligned with the agar plate, and the positive 
clones were picked using p200 pipette tips. The selected 
plaque was placed in 500 uL Lambda dilution buffer (0.1 M 
NaCl, 10 mM MgSO4, 3.5 mM Tris and 0.01% gelatin), 
vortexed for 30 s and kept at 4° C. The positive clones under 
went secondary immuno screening with the hyperimmune rat 
serum and rat-pre-immunisation serum as negative control to 
exclude false positive clones. 
Sequence Analyses 
Clones isolated from the cDNA library were ampli?ed by 
PCR using vector-speci?c primers and sequenced at the Uni 
versity of Kentucky’ s Advanced Genetic Technology Center. 
The resulting sequences were used as queries in BLASTN 
searches against non-human, non-mouse nucleotide 
sequences and BLASTX searches against the non-redundant 
protein database from NCBI. The presence of a signal peptide 
was predicted using SignalP 4.0, the presence of glycosyla 
tion sites were analysed using the ExPASy Prosite, and the 
presence of transmembrane domains and protein localisation 
were predicted using TMHMM 2.0 server. Pairwise align 
ment and phylogenetic comparison was performed using the 
ClustalOmega software on the EBI-server. Homologues from 
Cylicoslephanus goldi (University of Liverpool) and P. equo 
rum (University of Berlin) were obtained and the partial 
sequences compared by pairwise alignment using the Clusta 
lOmega software. 
Expression of Recombinant Protein 
Primers were designed to amplify the coding sequence 
from an immune-reactive cDNA clone for subcloning into a 














and reverse: 5'-GATCCTCGAGTCCCTTCATAGCGTCC-3' 
which incorporated the NdeI and XhoI restriction sites 
(CATATG and CTCGAG) to allow for unidirectional cloning. 
The PCR was performed using Verbatim High Fidelity Poly 
merase (Thermo Fisher Scienti?c, Pittsburgh, Pa.) and the 
ampli?ed fragment was digested with NdeI and XhoI and 
ligated with the pET22b(+) plasmid. The resulting plasmid 
was transformed into E. coli BL21 cells and expression of the 
recombinant protein was induced by 1 mM isopropyl-[3-D 
thiogalactopyranoside (IPTG) at an OD6OOM of 0.6 and the 
cells were incubated under agitation for 9 h at 300 C. The 
recombinant protein was puri?ed on immobilised cobalt by 
af?nity chromatography using BD TALON resin (Clontech, 
MountainView, Calif.) as per the manufacturer’ s protocol for 
soluble proteins. Puri?ed recombinant protein was stored in 
aliquots at —20° C. 
Hyperimmune Serum Against Recombinant Protein 
A total of 300 ug of recombinant protein was resolved in 
12% polyacrylamide gels under reducing conditions, a strip 
of the gel was stained with GelCode Blue stain (Thermo 
Scienti?c, Pittsburgh, Pa.) to verify where the recombinant 
antigen travelled in the gel and the corresponding part of the 
gel containing the desired molecular size was cut out and 
shipped to Cocalico Biologicals, Inc. (Reamstown, Pa.) and 
used to immunise a guinea pig with Freund’s complete adju 
vant for initial immunisation and Freund’s incomplete adju 
vant for subsequent boosters. The guinea pig was immunised 
by 6 inoculations of recombinant antigen over a period of 17 
weeks. 
Western Blot Analyses 
S. vulgaris ES 
For Western blot (WB) analysis of anti-adult S. vulgaris ES 
rat serum against both S. vulgaris larval and adult ES antigens 
were mixed with SDS-PAGE sample buffer containing pro 
tein inhibitor cocktail under reducing conditions and resolved 
in two 1-well 12% polyacrylamide gels. The proteins were 
transferred to 0.45 pm nitrocellulose membranes by semidry 
electrophoretic transfer in Tris-glycine buffer. Membranes 
were blocked for 1 h in PBST (PBS+0.05% Tween-20), and 
probed with pre-immunisation rat serum at 1:100 in PBST or 
hyperimmune rat serum raised against S. vulgaris adult ES at 
1:100 in PBST. The signal was developed using TMB stabi 
lised substrate for HRP (Promega, Madison, Wis.). 
For WB analysis of anti-recombinant protein guinea pig 
serum against larval ES, 4.4 ug S. vulgaris larval ES was 
resolved in a 1-well 12% polyacrylamide gels, transferred to 
a nitrocellulose membrane and blocked. The nitrocellulose 
membrane was cut and strips were placed in individual trays. 
The strips were probed with either 500 uL of guinea pig 
pre-immunisation serum at 1:500 in PBST or guinea pig 
hyperimmune serum anti-recombinant protein at 1:2,500 in 
PBST. HRP-conjugated goat anti-horse IgG(T) (Bethyl 
Laboratories, Inc., Montgomery, Tex., USA), were used as 
secondary antibodies at 1:10,000 in PBST. The signal was 
developed using Supersignal WestPico chemiluminescent 
substrate (Pierce, Rockford, Ill.). 
Recombinant Protein 
Recombinant protein (233 ng) was resolved in each two 
1-well 12% polyacrylamide gels by SDS-PAGE under reduc 
ing conditions and transferred to nitrocellulose membranes. 
The membranes were blocked and one was placed in a multi 
slot apparatus (Bio Rad, Hercules, Calif.). The blot was 
probed with 500 uL horse serum samples (1 :50 in PBST) in 
each slot. As secondary antibodies, HRP-conjugated goat 
anti-horse IgG(T) (Bethyl Laboratories, Inc., Montgomery, 
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Tex.), were used at 1:10,000 in PBST. The signal was devel 
oped using Supersignal WestPico chemiluminescent sub 
strate. 
Strips were cut from the other blocked blot and placed in 
individual trays. The strips were probed with either pre-im 
munisation guinea pig serum at 1:500 in PBST or anti-recom 
binant protein guinea pig serum at 1:2500 in PBST. As sec 
ondary antibody, HRP-conjugated donkey anti-guinea pig 
IgG (H+L) (Jackson ImmunoResearch, Inc., West Grove, Pa.) 
were used at 1:10,000 in PBST. The signal was developed 
using Supersignal WestPico chemiluminescent substrate. 
ELISA 
The indirect ELISA was optimised by sequential checker 
board titration to the following setup. Individual wells of a 96 
well EIA/RIA plate (Costar® easy-wash, Coming Inc., Com 
ing, N.Y.) were coated with 75 uL of recombinant protein 
diluted to 0.1 ug/mL in PBS and incubated overnight at 4° C. 
The wells were washed three times for 1 min with PBST and 
blocked for 11/2 h at RT with 200 uL block solution (PBS 
containing 5% normal goat serum, 1% dry milk powder and 
1% Tween-20). The wells were washed once and 75 uL of 
horse serum diluted 1 :50 in diluent solution (block solution in 
PBST, 1:10) was added to individual wells in duplicates and 
incubated for 1 h at 370 C. Positive, negative and blank 
controls were included on each plate in duplicates. The wells 
were washed ?ve times with PBST, and 75 uL of HRP 
conjugated goat anti-horse IgG (H+L) (Jackson ImmunoRe 
search, Inc. West Grove, Pa.) diluted 1:10,000 was added to 
each well and incubated for 1 h at 370 C. The wells were 
washed ?ve times with PBST and incubated for 10 min at RT 
in the dark with 75 uL of RT 1-step Ultra TMB ELISA 
substrate (Therrno Scienti?c, Rockford, Ill.) per well. The 
reactions were stopped with 75 uL 2M H2SO4 per well, and 
the OD450nm determined using an E-max Precision Micro 
plate Reader (Molecular Devices, Sunnyvale, Calif.) with a 
photometric range of 0.000 to 4.000 OD and a resolution of 
0.001 OD. 
IgG Subclass Antibodies 
For evaluation of the optimal diagnostic antibody target in 
serum from 15 horses with known S. vulgaris larval infection 
status the level of antigen speci?c IgG subclasses IgGa, Ing, 
Ich and IgG(T) were evaluated using HRP-conjugated goat 
anti-horse IgGa, Ing, Ich and IgG(T) antibodies (Bethyl 
Laboratories, Inc., Montgomery, Tex.) at 1:40,000 as second 
ary antibodies as per the manufacturer’s recommendation 
alongside the HRP-conjugated goat anti-horse IgG (H+L) 
secondary antibody as described in the ELISA setup. 
After identifying the best antibody target, the secondary 
antibody dilution for the ELISA was optimised by checker 
board titration. 
Diagnostic Accuracy of ELISA 
These ELISAs were performed in June and July, 2012. 
Serum samples from all horses (n:102) and horses seven 
months and older (n:86) were evaluated for the level of 
antigen speci?c IgG and IgG(T) antibodies using the opti 
mised ELISA in separate assays. The intra-assay variability 
of the ELISA was calculated from duplicate measurements 
from all horses. The inter-assay variability was calculated 
from the positive and negative controls included in each assay 
as well as speci?cally for three horses that were selected on 
the basis of their rSvSXP-speci?c IgG(T) OD450nm. (OD 
value given in parentheses). These animals served as a high 
positive (2.708), an intermediate positive (1.278) and a nega 
tive (0.022). From each sample, a volume of 1,000 uL of 
serum diluted 1:50 in diluent solution was prepared to test 












inter-assay variability as a normalised value, percentage of a 
positive control (PP), as previously described. 
Statistical Analyses 
The statistical program R, version 2.12 was used to gener 
ate graphs and perform statistical analyses. For all statistical 
analyses, a P-value less than or equal to 0.05 was considered 
signi?cant. 
Evaluation of IgG Subclasses 
The non-parametric Wilcoxon rank sum test was used to 
compare IgG levels within each IgG subclass between S. 
vulgaris infected and uninfected horses. 
Intra- and Inter-Assay Variability 
The intra- and inter-assay % coef?cient of variability (% 
CV) was calculated for each series of assays for each of the 
secondary antibodies. An intra-assay % CV below 10% and 
an inter-assay % CV below 20% were considered acceptable. 
Receiver Operator Characteristics (ROC) Curve Analysis 
ROC curve analyses were performed using the software 
package Epi for R for two sets of horses: all horses (n:102) 
and horses seven months or older (n:86). The reason for 
excluding foals in the second analysis was due to observa 
tions of high larval counts and corresponding low PP-values 
in some of the younger foals. After excluding horses younger 
than three months of age the remaining horses were all seven 
months or older. The cut-off was determined on the basis of 
the ROC curve analysis. 
Diagnostic Accuracy 
For the two sets of horses: all horses and horses 7 months 
and older the software package EpiR for R was used to cal 
culate the diagnostic accuracy values; sensitivity, speci?city, 
odds ratio, positive likelihood ratio (LR), and negative LR 
with corresponding 95% con?dence intervals. 
Correlation of Arterial S. vulgaris Larvae and rSvSXP 
Speci?c Antibodies 
The correlation between the number of S. vulgaris larvae in 
the cranial mesenteric artery and branches and the level of 
rSvSXP speci?c IgG(T)-antibodies expressed as the norma 
lised PP-value was evaluated by the Spearman correlation test 
from the software package fBasics for R. 
All horses (n:102) were categorised by the number of 
larvae present in the CMA and branches in the following ?ve 
groups: Group 0: No larvae, migratory tracts or evidence of 
previous infection (n:42); group 1: No larvae, but migratory 
tracts or evidence of previous infection (n:16); group 2: 1-5 
larvae (n:16); group 3: 6-25 larvae (n:17); and group 4: 
above 25 larvae (range: 25-292) (n:11). 
A subset of the horses, horses 7 months or older (n:86), 
were categorised by the number of S. vulgaris larvae in the 
CMA and branches in the following ?ve groups: Group 0: No 
larvae, migratory tracts or evidence of previous infection 
(n:28); group 1: Migratory tracts or evidence of previous 
infection (n:16); group 2: 1-5 larvae (n:16); group 3: 6-25 
larvae (n:17); and group 4: above 25 larvae (range: 25-200) 
(n:9). 
The relationship between the different groups and the PP 
values was evaluated graphically for both sets of horses. A 
Kruskal-Wallis test was performed to evaluate if there was a 
signi?cant difference between groups and a multiple com 
parison test after Kruskal-Wallis performed to identify the 
signi?cantly different groups using the statistical software 
package pgirmess for R. This was performed on both sets of 
horses. 
Results 
Preliminary Characterization of ES and Rat Anti-ES 
Serum 
The silver staining of the polyacrylamide gel showed a 
diverse mixture of molecules in both S. vulgaris larval and 
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adult ES (FIG. 1). The hyperimmune rat serum that was raised 
against S. vulgaris adult ES recognized more molecules in the 
adult ES than it did in the larval ES (FIG. 1). 
cDNA Library and Immunoscreening 
Titre analysis indicated that the primary unampli?ed 
cDNA library contained 4.75><106 plaque forming units (pfu)/ 
mL. Thirty plaques were randomly selected from the library, 
and PCR analysis showed that 28 of the clones had inserts 
(93.3%) and that 26 of the 28 (92.9%) had inserts larger than 
or equal to 500 bp. Based on BLASTx searches, sequence 
analysis of the 26 large-insert clones from the quality assess 
ment indicated that they all coded for different gene products. 
Horse serum from naturally infected horses was initially used 
for immunoscreening of the cDNA library; however, strong 
levels of anti-E. coli antibodies in the horse serum resulted in 
high background staining that could not be controlled. 
The primary immunoscreening of 100,000 clones in the 
unampli?ed larval S. vulgaris cDNA library yielded 28 posi 
tive clones, all of which con?rmed positive on secondary 
immunoscreening. The PCR products of these were all of 
comparable size (~650-680 bp) and sequence results of eight 
slightly different sized clones con?rmed that their cDNAs 
coded for the same protein. The sequence encodes 146 amino 
acids including a predicted signal peptide (18 amino acids), 
giving rise to a mature peptide of 128 amino acids with an 
estimated molecular weight of 13.57 kDa. No glycosylation 
sites were predicted and the protein did not have any predicted 
transmembrane domains. The predicted translation showed 
that the encoded protein is homologous to the SXP/RAL-2 
group of nematode speci?c proteins that contain a conserved 
Serine-X-Proline motif giving rise to the name. The protein 
was designated SvSXP. One sequence represented a full 
length cDNA coding sequence, which was deposited [Gen 
Bank: KC155360]. SvSXP had highest amino acid sequence 
similarity with a partial sequence from the Cylicoslephanus 
goldi homologue, followed by the surface-associated antigen 






both blots. The pre-immunisation guinea pig serum did not 
react against the 14 kDa recombinant antigen (FIG. 3). 
Western Blot Analyses of IgG Antibodies Against rSvSXP 
in S. vulgaris-Positive and Negative Horses 
The immunodiagnostic potential of antigen-speci?c IgG 
and IgG(T) antibodies against rSvSXP were evaluated by 
WB. These analyses revealed limited IgG reactivity to 
rSvSXP in serum from two horses not infected with S. vul 
garis and low level IgG(T) reactivity to rSvSXP in serum 
from eight horses not infected with S. vulgaris (FIG. 4), as 
determined by post-mortem examination. In contrast, serum 
from seven horses infected with S. vulgaris showed a reaction 
to rSvSXP (FIG. 4). 
Diagnostic Potential of IgG Subclass Antibodies 
Analysis of rSvSXP-speci?c IgG subclasses by ELISA 
showed that detection of rSvSXP-speci?c IgG(T) antibodies 
gave the clearest distinction between the seven S. vulgaris 
positive horses and the eight S. vulgaris negative horses, 
while the other IgG subclasses were less consistent (FIG. 5). 
Both the IgG subclasses IgGa (P:0.016) and IgG(T) 
(P:0.016) as well as total IgG (P:0.032) showed statistically 
signi?cant differences between infected and non-infected 
horses (n:15). 
Inter- and Intra-Assay Coef?cients of Variability 
The intra-assay variability of the ELISA measuring 
rSvSXP-speci?c IgG(T) antibodies was 9.17% for all the 
duplicate measurements. For the IgG(T) assays that were 
included, the inter-assay % CV for the positive control was 
16.9% while the inter-assay % CV for the negative control 
was 72.6% resulting in an overall inter-assay % CV of 44.8%. 
When using the PP-value, the overall inter-assay % CV 
dropped to 15.6%. The overall inter-assay % CV for the IgG 
assays, all measured on the same day, was 11.8%. 
Horse Material Used for Evaluation of Diagnostic Values 
of the ELISA 
The prevalence of arterial lesions as well as the seropreva 
lence in each group of horses is shown in Table 1. 
TABLE 1 
Prevalence of Slrongylus vulgaris expressed as prevalence of 
arterial lesions and seropositive horses. Sensitivity (Se) and 
speci?city (Sp) is presented for each group of horses. 
Prevalence Seropositive 
Group of horses of arterial lesions prevalence Se Sp 
KY, naturally infected, never 100% 90.1% 90.9% 100% 
treated herd (n = 1 1) 
KY, naturally infected, treated herd (n = 20) 10% 5% 50% 100% 
TN, naturally infected (11 = 23) 73.9% 87.0% 94% 33% 
TN, experimentally infected with 70% 50% 64% 83% 
P. equorum (n = 20) 
TN, experimentally infected with 
S. vulgaris and Cyathostomins (n = 28) 57.1% 39.3% 50% 75% 
Case de?nition: A S. vulgaris positive horse has presence of larvae, migratory tracts or healing lesions 
Cut-offvalue used: seropositive: PP-value above 8.75. 
ACE79378 . 1 ] , and thirdly the immunodominant-hypodermal 
antigen AC16 from Ancylosloma caninum [Genbankz 
ABD98404.1]. Two partial sequences from a P. equorum 
derived homologue had a lesser degree of similarity (35% and 
46% identities) (FIG. 2A). The phylogenetic comparison 
clustered C. goldi with S. vulgaris, P equorum with Ascaris 
suum and N. americanus with A. caninum (FIG. 2B). 
Analysis of SvSXP in S. vulgaris Larval ES 
Western blot analyses of rSvSXP and larval ES using 
hyperimmune guinea pig anti -rSvSXP serum showed that the 




A total of 42 horses showed no signs of migrating larvae in 
the CMA and branches or signs of previous infection and 
were classi?ed as S. vulgaris-negative, larvae with migratory 
tracts and evidence of thrombosis were found in 47 horses, 
and migratory tracts or healing lesions were found in 19 
horses, of these 10 were determined to show evidence of a 
previous infection. 
In the subset of horses seven months or older, 29 were 
classi?ed as S. vulgaris-negative with no sign of current or 
previous infection; 42 horses had migrating larvae, migratory 
tracts and evidence of thrombosis; 17 horses had migratory 
tracts or healing lesions but no larvae, of these seven were 
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determined to show evidence of a previous infection. The 
relationship between numbers of migrating arterial S. vul 
garis larvae and ELISA results is illustrated in FIG. 6. In the 
full dataset there was a signi?cant difference in the level of 
anti-SvSXP lgG(T) antibodies, expressed as the PP-value, 
between S. vulgaris-negative horses (Group 0) and horses 
with migrating larvae (groups 2,3 and 4). In the subset of 
horses seven months and older there was a signi?cant differ 
ence between the same groups as well as a signi?cant differ 
ence between horses with no larvae but evidence of migratory 
tracts, aneurysm or healing lesions (group 1), and horses with 
a heavy infection (group 4). 
A moderate positive correlation was found between the 
number of S. vulgaris larvae in the CMA and branches and the 
PP-value with an RS of0.5779 (0.433-0.693), P<0.0001 in the 
data set including all horses. In the data set including horses 
7 months and older there was a moderate positive correlation 
between the number of S. vulgaris larvae in the CMA and 
branches and the PP-value with an RS of 0.5944 (0.44-0.714), 
P<0.0001 . 
Diagnostic Accuracy 
The relationship between sensitivity and speci?city is 
listed for the two datasets at different cut-off values (Table 2). 
TABLE 2 
Sensitivity and speci?city at different cut—off values of antibody 
responses against rSvSXP expressed as percent of a positive 
control (PP) for (A) all horses (11 = 102) or (B) horses 7 
months or older (11 = 86). 
Data set A B 
PP cut—off Se$ Sp$ Se Sp 
5 0.77 0.67 0.78 0.54 
10 0.70 0.83 0.71 0.75 
15 0.64 0.88 0.66 0.82 
20 0.53 0.88 0.55 0.82 
25 0.48 0.90 0.50 0.86 
30 0.42 0.98 0.43 0.96 
40 0.37 1 0.38 1 
50 0.32 1 0.33 1 
60 0.27 1 0.28 1 
70 0.22 1 0.22 1 
80 0.17 1 0.17 1 
90 0.12 1 0.12 1 
100 0.08 1 0.09 1 
>100 0.05 1 0.02 1 
AUC$ 0.820 0.783 
is: Se: sensitivity; Sp: speci?city; AUC: area under ROC curve. 
The diagnostic accuracy values expressed as sensitivity, 
speci?city, diagnostic odds ratio, LR+ and LR— for each set of 
horses are shown for the optimal cut-off PP value in Table 3. 
TABLE 3 
Diagnostic accuracy values with 95% con?dence 
intervals using the same cut—off value for (A) all 
horses (11 = 102) or (B) horses 7 months or older (11 = 86). 
Data set: A B 
Cut—offvalue (PP) 8.75 13.47 
86 73.3% (60.3-83.9%) 65.5% (51.9-77.5%) 
Sp 81.0% (65.9-91.4%) 82.1% (63.1-93.9%) 













Diagnostic accuracy values with 95% con?dence 
intervals using the same cut—off value for (A) all 
horses (11 = 102) or (B) horses 7 months or older (11 = 86). 
Data set: A B 
Cut—offvalue (PP) 8.75 13.47 
LR+ 3.85 (2.03-7.32) 3.67 (1.62-8.30) 
LR— 0.33 (0.21-0.51) 0.42 (0.28-0.62) 
Cut-off values represent optimal sensitivity and speci?city for each case-de?nition. PP: 
percent ofa positive control; Se: sensitivity; Sp: speci?city; DOR: diagnostic odds ratio; 
LR+: positive likelihood ratio; LR—: negative likelihood ratio. The 95 % con?dence intervals 
are given in parentheses. 
Accordingly, the present protein meets at least four criteria: 
(i) the recombinant protein was bound by serum lgG(T) pri 
marily from horses harboring infection or exhibiting lesions 
associated with previous presence of S. vulgaris larvae; (ii) 
the diagnostic odds ratio of the ELISA showed that infection 
with migrating S. vulgaris larvae signi?cantly increased the 
possibility of a positive test result; (iii) other naturally occur 
ring equine gastrointestinal nematodes did not appear to inter 
act with test results; (iv) there is evidence of a semi-quanti 
tative relationship between infection intensity and ELISA 
results. 
The data generated in this Example is from horses being 
either naturally or experimentally infected with major equine 
helminth parasites. The experimental infections withP. equo 
rum and cyathostomin parasites did not appear to dramati 
cally affect diagnostic performance (Table 1). Further, four 
out of ?ve of the de?ned subpopulations returned higher 
sensitivity than speci?city. It is considered useful to evaluate 
the diagnostic odds ratio (DOR) and the likelihood ratios 
(LR) that are presented in Table 3. The DORs were high and 
statistically signi?cant, and the test is characterized by a 
strong positive LR. High levels of cross-reactivity with other 
species and stages would have led to more false-positive test 
results, and, thus, a lower positive LR. Taken together, 
rSvSXP represents a well-characterized and validated diag 
nostic antigen for S. vulgaris diagnosis. 
As the hyperimmune rat serum was raised against adult S. 
vulgaris ES antigens and this was used to perform the immu 
noscreening of the S. vulgaris larval cDNA library, the protein 
is expressed in both larval and adult stages. Thus, it is possible 
that adult stages in the intestine are also capable of affecting 
ELISA measurements. lgG(T) antibodies in some animals 
does not differ from the non-speci?c background reactivity in 
controls, suggesting that the immune response and hence 
antibody production is primarily stimulated by the migrating 
larvae and not the adult worms. Therefore, it is possible that 
the presence of the larvae in the blood stream of the horse will 
allow a higher degree of exposure of the SXP protein to the 
immune system. 
Here, IgG(T) antibodies speci?c to rSvSXP appeared to 
have a immunodiagnostic potential than other IgG subclasses 
(FIGS. 5 and 6). The intra-assay % CV of mean OD450nm 
values was within acceptable levels and the inter-assay % CV 
was higher. The use of the normalised PP value reduced the 
inter-assay % CV. 
The semi-quantitative potential of the procedure is illus 
trated in FIG. 6. A separate analysis was performed in horses 
older than seven months to evaluate if the ELISA would 
perform better in this age group. FIGS. 6a and 6b seems to 
indicate that larval burden and the PP-value correlate more 
closely when foals were excluded. This illustrates that 
younger foals can harbor migrating larvae without producing 
antibody titres. 
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The ELISA performed with a sensitivity and speci?city 
comparable to larval cultures carried out for detection of S. 
vulgaris eggs, and has potential for re?ecting the number of 
arterial larvae. The odds of a PP-value above the cut-off 
among horses with migrating S. vulgaris larvae, migratory 
tracts or evidence of previous infection was 1 1.7 times higher 
than the odds of a similar ELISA result among horses without 
migrating S. vulgaris larvae or signs thereof. Moreover, a high 
PP-value indicates a high number of migrating larvae (FIG. 
6). 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 9 
<210> SEQ ID No 1 
<211> LENGTH: 146 
<212> TYPE: PRT 
<213> ORGANISM: Strongylus vulgaris 
<400> SEQUENCE: 1 
Met Leu Lys Ile Val Ala Leu Ala Cys Leu Ala Val Ile Cys Leu Val 
1 5 1 o 1 5 
Lys Ala Gln Asn Gly Pro Pro Pro Phe Leu Gln Lys Ala Pro Ala Ala 
2 o 2 5 3 0 
Val Gln Lys Glu Phe Glu Gly Leu Phe Ala Asn Ala Gly Ser Met Thr 
3 5 4 o 4 5 
Asp Ala Ala Ile Asp Lys Met Val Lys Asp Trp Val Ala Lys Gln Ser 
5 o 5 5 6 0 
Ala Glu Ile Lys Thr Ala Phe Ala Ala Phe Glu Lys Glu Ile Gln Ser 
6 5 7 o 7 5 s 0 
Ala Gln Ala Gln Gly Glu Ala Ala His Gln Ala Ala Ile Ala Lys Phe 
s 5 9 o 9 5 
Ser Pro Ala Ala Lys Glu Ala Asp Ala Lys Leu Thr Ala Ile Ala Asn 
1 o o 1 o 5 1 1 o 
Asp Arg Ser Lys Thr Asn Ala Gln Lys Gly Ala Glu Ile Asp Gly Ile 
1 1 5 1 2 o 1 2 5 
Leu Lys Ala Leu Pro Glu Lys Val Arg Lys Glu Ile Glu Asp Ala Met 
1 3 o 1 3 5 14 o 
Lys Gly 
14 5 
<210> SEQ ID No 2 
<211> LENGTH: 69 
<212> TYPE: PRT 
<213> ORGANISM: Cylicostephanus goldi 
<400> SEQUENCE: 2 
Met Leu Lys Ile Val Ala Leu Ala 
l 5 10 
Gln Ala Gln Gln Gly Pro Pro Pro 
20 25 
Cys Leu Ala Val Ile Cys Leu Ala 
15 
Phe Leu Ala Ser Ala Pro Pro Ala 
30 
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—cont inued 
Val Gln Lys Glu Phe Glu Gly Leu Phe Ala Asn Ala Asp Lys Met Thr 
35 4O 45 
Asp Ala Glu Ile Asp Lys Met Val Lys Asp Trp Ile Gly Lys Gln Ser 
50 55 6O 
Asp Ala Val Lys Thr 
65 
<210> SEQ ID NO 3 
<211> LENGTH: 146 
<212> TYPE: PRT 
<213> ORGANISM: Necator americanus 
<400> SEQUENCE: 3 
Met Leu Lys Leu Val Ala Leu Val Cys Leu Val Ala Ile Cys Phe Ala 
1 5 10 15 
Gln Gly Pro Gln Gly Pro Pro Pro Phe Leu Gln Ser Ala Pro Ala Ala 
20 25 30 
Val Gln Gln Asp Phe Asp Lys Leu Phe Val Asn Ala Gly Ser Lys Thr 
35 4O 45 
Asp Ala Glu Ile Asp Lys Met Val Gln Asp Trp Val Gly Lys Gln Asp 
5O 55 6O 
Ala Ser Ile Lys Thr Ala Phe Asp Ala Phe Val Lys Glu Val Lys Ala 
65 7O 75 8O 
Ala Gln Ala Gln Gly Glu Ala Ala His Gln Ala Ala Ile Ala Lys Phe 
85 90 95 
Ser Ala Glu Ala Lys Ala Ala Asp Ala Lys Leu Ser Ala Ile Ala Asn 
100 105 110 
Asp Arg Ser Lys Thr Asn Ala Gln Lys Gly Ala Glu Ile Asp Ser Val 
115 120 125 
Leu Lys Gly Leu Pro Pro Asn Val Arg Thr Glu Ile Glu Asn Ala Met 
130 135 140 
Lys Gly 
145 
<210> SEQ ID NO 4 
<211> LENGTH: 147 
<212> TYPE: PRT 
<213> ORGANISM: Ancylostoma caninum 
<400> SEQUENCE: 4 
Met Leu Lys Leu Val Ala Leu Ala Cys Leu Ala Ala Ile Cys Leu Ala 
1 5 10 15 
Gln Gly Gly Pro Glu Gly Pro Pro Pro Phe Leu Lys Ser Ala Pro Pro 
20 25 3O 
Glu Lys Val Thr Glu Phe Asp Ala Leu Phe Ala Asp Ala Gly Gly Leu 
35 4O 45 
Thr Asp Ala Gln Ile Asp Ala Lys Val Lys Gly Trp Ile Gly Lys Gln 
5O 55 6O 
Ser Gln Asp Ile Gln Ser Ala Phe Asn Ala Phe Glu Ser Glu Val Lys 
65 7O 75 8O 
Ala Ala Gln Gln Gln Gly Glu Gln Ala His Gln Ala Ala Val Ala Lys 
85 90 95 
Phe Ser Ala Glu Ala Lys Ala Ala Asp Ala Lys Leu Thr Ala Ile Ala 
100 105 110 
Asn Asp Ala Ser Lys Thr Asn Ala Gln Lys Gly Ala Glu Ile Asp Ala 
115 120 125 
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—cont inued 
Val Leu Lys Gly Leu Pro Gln Lys Val Arg Asp Glu Ile Glu Asn Ala 
130 135 140 
Met Lys Gly 
145 
<210> SEQ ID NO 5 
<211> LENGTH: 146 
<212> TYPE: PRT 
<213> ORGANISM: Ascaris suum 
<400> SEQUENCE: 5 
Met Lys Val Leu Ile Ile Phe Val Ala Ile Val Val Ile Ala Phe Ala 
1 5 10 15 
Gln Gly Pro Gln Gly Pro Pro Pro Phe Leu Val Gly Ala Pro Ala Asn 
2O 25 30 
Val Val Ala Glu Phe Lys Gln Ile Ile Thr Gly Ala Pro Asp Lys Thr 
35 4O 45 
Asp Ala Glu Ile Asp Arg Asp Ile Glu Asn Trp Val Ala Arg Gln Gly 
50 55 60 
Pro Lys Ile Lys Thr Glu Phe Asn Lys Phe Lys Thr Gln Met Gln Gln 
65 7O 75 8O 
Gly Lys Ala Arg Ala Glu Ala Ala His Arg Ala Ser Ile Ala Lys Phe 
85 90 95 
Ser Pro Ala Ala Lys Ala Ala Asp Ala Gln Leu Thr Ala Ile Ala Asp 
100 105 110 
Asn Pro Asn Leu Lys Gly Arg Glu Lys Gln Gln Lys Ile Thr Gly Leu 
115 120 125 
Leu Gln Ser Leu Pro Ala Ala Val Gln Ala Glu Phe Gln Lys Glu Met 
130 135 140 
Gln Gly 
145 
<210> SEQ ID NO 6 
<211> LENGTH: 146 
<212> TYPE: PRT 
<213> ORGANISM: Ascaris lumbricoides 
<400> SEQUENCE: 6 
Met Lys Val Leu Ile Ile Phe Phe Ala Ile Val Val Ile Ala Phe Ala 
1 5 10 15 
Gln Gly Pro Gln Gly Pro Pro Pro Phe Leu Val Gly Ala Pro Ala Asn 
2O 25 30 
Val Val Ala Glu Phe Lys Gln Ile Ile Thr Gly Ala Pro Asp Lys Thr 
35 4O 45 
Asp Ala Glu Ile Asp Arg Asp Ile Glu Asn Trp Val Ser Arg Gln Gly 
50 55 60 
Pro Lys Ile Lys Thr Glu Phe Asn Lys Phe Lys Thr Gln Met Gln Gln 
65 7O 75 8O 
Gly Lys Ala Arg Ala Glu Ala Ala His Gln Ala Ser Ile Ala Lys Phe 
85 90 95 
Ser Pro Ala Ala Lys Thr Ala Asp Ala Gln Leu Thr Ala Ile Ala Asp 
100 105 110 
Asn Pro Asn Leu Lys Gly Arg Glu Lys Gln Gln Lys Ile Thr Ser Leu 
115 120 125 
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—cont inued 
Leu Gln Ser Leu Pro Ala Ala Val Gln Ala Glu Leu Gln Lys Glu Met 
130 135 140 
Gln Gly 
145 
<210> SEQ ID NO 7 
<211> LENGTH: 131 
<212> TYPE: PRT 
<213> ORGANISM: Parascaris equorum 
<400> SEQUENCE: 7 
Leu Ile Ile Phe Ile Ala Ile Ala Gly Ile Ala Phe Ala Gln Gly Gln 
1 5 10 15 
Gln Gly Glu Gln Gly Pro Pro Pro Phe Leu Val Gly Ala Pro Ala Lys 
20 25 30 
Val Val Ala Glu Phe Lys Gln Leu Val Asn Gly Ala Pro Asp Lys Thr 
35 4O 45 
Asp Ala Glu Val Asp Arg Asp Ile Glu Asn Trp Ile Ala Arg Gln Glu 
Pro Lys Val Lys Thr Glu Phe Asn Lys Phe Lys Thr Gln Met Arg Phe 
65 7O 75 8O 
Ser Pro Ala Ala Lys Ala Ala Asp Ala Gln Leu Thr Ala Ile Ala Asp 
85 9O 95 
Asn Pro Asn Leu Lys Gly Arg Glu Lys Gln Gln Lys Ile Thr Ser Leu 
100 105 110 
Leu Gln Ser Leu Pro Ala Ala Val Gln Ala Glu Leu Gln Lys Glu Met 
115 120 125 
Gln Gly Thr 
130 
<210> SEQ ID NO 8 
<211> LENGTH: 13 
<212> TYPE: PRT 
<213> ORGANISM: Strongylus vulgaris 
<220> FEATURE: 
<221> NAME/KEY: x 
<222> LOCATION: (1)..(1) 
<223> OTHER INFORMATION: X is AhX 
<400> SEQUENCE: 8 
Xaa Phe Ala Asn Ala Gly Ser Met Thr Asp Ala Ala Ile 
1 5 10 
<210> SEQ ID NO 9 
<211> LENGTH: 15 
<212> TYPE: PRT 
<213> ORGANISM: Strongylus vulgaris 
<400> SEQUENCE: 9 
Ala Phe Ala Ala Phe Glu Lys Glu Ile Gln Ser Ala Gln Ala Gln 
1 5 10 15 
What is claimed is: a polypeptide comprising an epitope of the polypeptide 
1. A method of diagnosing a Slrongylus vulgaris infection of SEQ ID NO; 1, wherein the epitope is selected from 
in a subject during a Preparer1t Period, comprising 60 C-Ahx-FANAGSMTDAAI-amide (svar-1)(SEQ ID 
(a) providing a biological sample from the subject; and NO, 8) and/or C_AFAAFEKEIQSAQAQ_amide 
(b) contacting the sample With a polypeptide comprising: (svar_2)(SEQ ID No: 9) or 
the polypeptide of SEQ ID NO: 1 and/ or a fragment _ _ ’ 
thereof comprising at least 145, 144, 143, 142, 141, a combmanon thereOf' 
140,139,138,137,136,135,134,133,132,131,130, 65 2. The method ofclaim 1, and further comprising detecting 
129, 128, 127, 126, 125, 124, 123, 122, 121, 120, 119, antibodies in the sample that speci?cally bind the polypep 
118, 117, 116, or 115 amino acid residues tide. 
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3. The method of claim 2, wherein the detection is con 
ducted using an enzyme-linked immunosorbent assay 
(ELISA). 
4. The method of claim 1, Wherein the subject is diagnosed 
as being infected by migrating S. vulgaris larvae When anti 
bodies that speci?cally bind the polypeptide are detected in 
the sample. 
5. The method of claim 1, Wherein the subject is a horse. 
6. The method of claim 1, Wherein the biological sample is 
a blood or serum sample. 
7. A method of diagnosing a Slrongylus vulgaris infection 
in a subject during a prepatent period, comprising: 
(a) providing a biological sample from the subject; and 
(b) contacting the sample With a puri?ed antibody that 
5 
10 
speci?cally binds to an epitope of the polypeptide of 15 
SEQ ID NO: 1. 
8. The method of claim 7, Wherein the epitope comprises 
the amino acid residues of SEQ ID NO: 1 selected from 
30 
C-AhX-FANAGSMTDAAI-amide (svar-l)(SEQ ID NO: 8) 
and/or C-AFAAFEKEIQSAQAQ-amide (svar-2)(SEQ ID 
NO: 9). 
9. The method of claim 7, and further comprising detecting 
a polypeptide in the sample to Which the antibody speci?cally 
binds. 
10. The method of a claim 9, Wherein the subject is diag 
nosed as being infected by migrating S. vulgaris larvae When 
the polypeptide to Which the antibody speci?cally binds is 
detected in the sample. 
11. The method of claim 9, Wherein the detection is con 
ducted using an enzyme-linked immunosorbent assay 
(ELISA). 
12. The method of claim 7, Wherein the subject is a horse. 
13. The method of claim 7, Wherein the biological sample 
is a blood or serum sample. 
* * * * * 
